Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: Clinical and experimental studies

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 727-737

  Kindt, Nadège ^a   Preillon, Julie ^a,d   Kaltner, Herbert ^b   Gabius, Hans Joachim ^b   Chevalier, Dominique ^c   Rodriguez, Alexandra ^d   Johnson, Bryon D ^e   Megalizzi, Véronique ^d   Decaestecker, Christine ^d   Laurent, Guy ^a   Saussez, Sven ^a,d  

^a UNIVERSITY OF MONS   (Belgium)

^b UNIVERSITY OF MUNICH   (Germany)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Head and neck squamous cell carcinoma; HNSCC; Macrophage migration inhibitory factor; MIF; SCCVII cells

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA CELL; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORPHOMETRICS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876297557     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1375-7     Document Type: Article

References (34)

1. Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimburger O et al (2009) Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med 15:70-75
2. Camlica H, Duranyildiz D, Oguz H, Oral EN, Yasasever V (2008) The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res 14:79-83
3. Chen RJ, Deng WG, Niu CB, Li YY, Fu Y (2011) Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer 21:1004-1012
4. Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S (2010) Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 30:3313-3319
5. Conroy H, Mawhinney L, Donnelly SC (2010) Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 103:831-836
6. Debeir O, Van Ham P, Kiss R, Decaestecker C (2005) Tracking of migrating cells under phase-contrast video microscopy with combined mean-shift processes. IEEE Trans Med Imaging 24:697-711
7. Debeir O, Megalizzi V, Warzée N, Kiss R, Decaestecker C (2008) Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res 314:2985-2998
8. Dumitru CA, Gholaman H, Trellakis S, Bruderek K, Dominas N, Gu X, Bankfalvi A, Whiteside TL, Lang S, Brandau S (2011) Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer 129:859-869
9. Filleul O, Preillon J, Crompot E, Lechien J, Saussez S (2011) Incidence of head and neck cancers in Belgium: comparison with worldwide and French data. Bull Cancer 10:1173-1183
10. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cell Ther 6:1993-2002
11. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR, Al-Abed Y (2009) Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 15:1-10
12. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, Nagasue N (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588-598
13. Hyams VJ, Batsakis JG, Michaels L (1988) Tumors of the Upper Respiratory Tract and Ear. In Atlas of Tumor Pathology, Washington DC, Armed Forces Institute of Pathology, pp 123-126
14. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89:334-341
15. Krockenberger M, Engel JB, Kolb J, Dombrowsky Y, Häusler SF, Kohrenhagen N, Dietl J, Wischhusen J, Honig A (2010) Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 136:651-657
16. Lee H, Rhee H, Kang HJ, Kim HS, Min BS, Kim NK et al (2008) Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 129:772-779
17. Leng L, Bucala R (2006) Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res 16:162-168
18. Li Z, Ren Y, Wu QC, Lin SX, Liang YJ, Liang HZ (2004) Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J 117:107-114
19. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4:449-460
20. Mitchell RA (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16:13-19
21. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR (1997) A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 123:20-24
22. Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242:55-63
23. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, Mitchell RA (2007) Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 282:29910-29918
24. Rendon BE, Willer SS, Zundel W, Mitchell RA (2009) Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 86:180-185
25. Santos LL, Morand EF (2008) Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 399:1-7
26. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, André S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R (2006) Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 13:999-1009
27. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595-606
28. Suzuki F, Nakamaru Y, Oridate N, Homma A, Nagahashi T, Yamaguchi S, Nishihira J, Furuta Y, Fukuda S (2005) Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep 13:59-64
29. Wang X-B, Tian X-Y, Li Y, Li B, Li Z (2012) Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neurooncol 106:43-51
30. Wittekind C, Greene FL, Hutter RVP (2004) TNM atlas. 5th ed. pp 20-32. UICC Springer: Berlin
31. Xiao DZ, Dai B, Chen J, Luo Q, Liu XY, Lin QX, Li XH, Huang W, Yu XY (2011) Loss of macrophage migration inhibitory factor impairs the growth properties of human HeLa cervical cancer cells. Cell Prolif 44:582-590
32. Yan X, Orentas RJ, Johnson BD (2006) Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33:188-198
33. Zeng F-Y, Weiser WY, Kratzin H, Stahl B, Karas M, Gabius HJ (1993) The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor? Arch Biochem Biophys 303:74-80
34. Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD (2008) Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol 181:1877-1886